<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868634</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-080-2</org_study_id>
    <secondary_id>2008-003779-37</secondary_id>
    <nct_id>NCT00868634</nct_id>
  </id_info>
  <brief_title>Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer</brief_title>
  <acronym>CARIN</acronym>
  <official_title>Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to detect the superiority of the triple combination of capecitabine,&#xD;
      bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in&#xD;
      patients with metastatic breast cancer. 600 patients, 300 in each treatment group, are&#xD;
      treated until progression of disease to determine PFS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>end of trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events and serious adverse events</measure>
    <time_frame>during the whole time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR = CR +PR)</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine / Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine / Bevacizumab / Vinorelbine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg i.v., day 1 Cycles are repeated every three weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg i.v., day 1. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Avastin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Navirel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Able to comply with the protocol.&#xD;
&#xD;
          -  ECOG Performance status 0 - 2.&#xD;
&#xD;
          -  Life expectancy more than 12 weeks.&#xD;
&#xD;
          -  Known ER / PR status.&#xD;
&#xD;
          -  Confirmed HER2/neu-negative, adenocarcinoma of the breast with measurable or&#xD;
             non-measurable locally recurrent or metastatic disease, who are candidates for&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Previous (neo)adjuvant chemotherapy is allowed provided that the last dose of&#xD;
             chemotherapy was applied more than 6 months prior to randomization.&#xD;
&#xD;
          -  Previous adjuvant radiotherapy is allowed as part of the treatment of early breast&#xD;
             cancer provided that no more than 30% of marrow-bearing bone was irradiated.&#xD;
&#xD;
          -  No signs and symptoms of CHF.&#xD;
&#xD;
          -  Adequate hepatic and renal function values.&#xD;
&#xD;
          -  Adequate hematologic function values.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Previous chemotherapy for metastatic or locally recurrent breast cancer.&#xD;
&#xD;
          -  Previous radiotherapy for the treatment of metastatic disease (unless given for the&#xD;
             relief of metastatic bone pain)&#xD;
&#xD;
          -  Evidence of spinal cord compression or current evidence of central nervous system&#xD;
             (CNS) metastases.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic in-jury within 28 days&#xD;
             prior to randomization, or anticipation of the need for major surgery during the&#xD;
             course of the study treatment.&#xD;
&#xD;
          -  History or evidence of inherited bleeding diathesis or coagulopathy with the risk of&#xD;
             bleeding.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg).&#xD;
             Clinically significant (i.e. active) cardiovascular disease, requiring medication&#xD;
             during the study and might interfere with regularity of the study treatment, or not&#xD;
             controlled by medication.&#xD;
&#xD;
          -  Non-healing wound, active peptic ulcer or bone fracture.&#xD;
&#xD;
          -  History of abdominal fistula, or any grade 4 nongastrointestinal fistula,&#xD;
             gastrointestinal perforation or intrabdominal abscess within 6 months of&#xD;
             randomization.&#xD;
&#xD;
          -  Active infection requiring i.v. antibiotics at randomization.&#xD;
&#xD;
          -  Clinically significant malabsorption syndrome or inability to take oral medication.&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or excipients.&#xD;
&#xD;
          -  Concurrent treatment with any drug interfering with study medication. Concurrent&#xD;
             participation in another clinical trial. Prior participation is allowed when the last&#xD;
             study medication was applied more than 4 weeks prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Hegewisch-Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onkologische Schwerpunktpraxis Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

